1 Boston University School of Medicine, Boston, MA, USA.
2 Hamad Medical Corporation, Doha, Qatar.
3 Hamad Medical Corporation, Doha, Qatar. firstname.lastname@example.org.
4 VA Pittsburgh Healthcare System, Pittsburgh, PA, USA. email@example.com.
5 Weill Cornell Medical College, New York, NY, USA. firstname.lastname@example.org.
6 Weill Cornell Medical College, Doha, Qatar. email@example.com.
PURPOSE OF REVIEW:
Direct acting antiviral agents (DAAs) have emerged as simple, short, safe, and effective treatments for chronic hepatitis C (CHC) infection. CHC is a systemic disease with frequent and multiple extrahepatic manifestations. The beneficial effects of DAA treatment regimens extend beyond improvement in liver-related outcomes to amelioration of extra hepatic manifestations and are likely to have economic implications. The purpose of this review is to evaluate the effect of DAAs on extra hepatic manifestations of CHC virus infection.
Recent studies indicate that DAAs are associated with reduction in all-cause mortality, even in patients without significant hepatic fibrosis. They are also associated with reduction in incident cardiovascular disease and diabetes. DAAs are the mainstay of treatment in HCV-associated cryoglobulinemia and lymphoma. Successful HCV therapy with DAAs also improves patient-related outcomes such as health-related quality of life. DAAs improve extrahepatic manifestations of CHC virus infection. Future studies are needed to evaluate the long-term durability of treatment response and for accounting amelioration of extrahepatic manifestations into the cost effectiveness of DAA regimens.